Skip to Main Content
BLACK FRIDAY SALE

60% off Quiver Premium for new subscribers

...

Use Promo Code:

BLACKFRIDAY26
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Jade Biosciences Posts $35.1 Million Third-Quarter Net Loss

None

Jade Biosciences (JBIO) reported a net loss of $35.1 million, or $0.42 per basic and diluted common share, for the third quarter ended September 30, 2026. The company held $475.7 million in cash, cash equivalents and investments at quarter-end.

Jade said it expects to initiate its Phase 3 EVERGREEN trial of JADE101 in IgA nephropathy and a Phase 1 trial of JADE301 in dermatomyositis during the fourth quarter of 2026.

  • Third-quarter research and development expense was $30.8 million, compared with $22.0 million a year earlier.
  • General and administrative expense was $8.8 million, compared with $5.4 million in the prior-year quarter.
  • JADE101 Phase 2 JUNIPER interim data are expected in the second quarter of 2027.
  • JADE201 Phase 1 interim data are expected in 2027, while JADE301 interim data are anticipated in the second half of 2027.
  • The company expects its existing cash, cash equivalents and investments to fund operations into the fourth quarter of 2028.
EARLY ACCESS
Receive JBIO Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$JBIO Hedge Fund Activity

We have seen 102 institutional investors add shares of $JBIO stock to their portfolio, and 54 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles